EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PELL Bio-Med Technology Co's Enterprise Value is NT$56,283.89 Mil.
PELL Bio-Med Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-508.89 Mil. Therefore, PELL Bio-Med Technology Co's EV-to-FCF for today is -110.60.
The historical rank and industry rank for PELL Bio-Med Technology Co's EV-to-FCF or its related term are showing as below:
TPE:6949'
s EV-to-FCF Range Over the Past 10 Years
Min: -109.44 Med: -27.59 Max: -7.3
Current: -109.44
During the past 5 years, the highest EV-to-FCF of PELL Bio-Med Technology Co was -7.30. The lowest was -109.44. And the median was -27.59.
TPE:6949's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 15.57
vs TPE:6949: -109.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PELL Bio-Med Technology Co (TPE:6949) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PELL Bio-Med Technology Co's PE Ratio (TTM) for today is calculated as:
PELL Bio-Med Technology Co's share price for today is NT$871.00.
PELL Bio-Med Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-7.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PELL Bio-Med Technology Co EV-to-FCF Related Terms
PELL Bio-Med Technology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6949 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, PELL Bio-Med Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PELL Bio-Med Technology Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PELL Bio-Med Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PELL Bio-Med Technology Co's EV-to-FCF falls into.
PELL Bio-Med Technology Co's current Enterprise Value is NT$56,283.89 Mil.
PELL Bio-Med Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-508.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PELL Bio-Med Technology Co (TPE:6949) has a EV-to-FCF of -110.60 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PELL Bio-Med Technology Co and its competitors. According to the industry distribution chart, PELL Bio-Med Technology Co ranks #999999 out of 331 companies in the Biotechnology industry.
Is PELL Bio-Med Technology Co's EV-to-FCF too high?
PELL Bio-Med Technology Co's current EV-to-FCF is -110.60. Based on the distribution chart, PELL Bio-Med Technology Co ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PELL Bio-Med Technology Co has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does PELL Bio-Med Technology Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PELL Bio-Med Technology Co ranks #999999 out of 331 companies for EV-to-FCF. This places PELL Bio-Med Technology Co in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PELL Bio-Med Technology Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PELL Bio-Med Technology Co's current EV-to-FCF is -110.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PELL Bio-Med Technology Co stock overvalued right now?
PELL Bio-Med Technology Co (TPE:6949) has a current EV-to-FCF of -110.60. The current EV-to-FCF is -110.60. PELL Bio-Med Technology Co's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PELL Bio-Med Technology Co (TPE:6949), the current EV-to-FCF is -110.60 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell). The company's segments includes Cell products, Consulting services, and Others.
13GF Score
Get the complete analysis for TPE:6949
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6949 has been successfully added to your 
